9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Autologous Dendritic Cell Vaccination in Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Autologous Dendritic Cell Vaccination in Mesothelioma

Autologous Dendritic Cell Vaccination in Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 20

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of MPM patients with feasible and safe DC vaccine production,  Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame,  Objective clinical responses by tumor evaluation (clinical efficacy), Overall survival (clinical efficacy)

Interventions: dendritic cell vaccination plus chemotherapy,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: October 2020

Completion Date: November 2021

Last  Posted Date: May 24, 2018

Location: Antwerp University Hospital, Edegem, Antwerp, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT02649829

Was this article helpful?
Dislike 0